Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca Divests Antidiabetics To 3SBio In New China Growth Plan

Executive Summary

AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.

Advertisement

Related Content

2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
Diabetes Tsunami? China Eyes More Modern Therapies Under 2025 Plan
Can An Elephant Crack China’s Bamboo Ceiling For Generics?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register